News Europe German Medical Cannabis Patients To Top One Million

German Medical Cannabis Patients To Top One Million



A REPORT into the German medical cannabis market estimates the number of patients totalled over 60,000 in less than two years since first approved.

The ‘Germany Cannabis Report’ from Prohibition Partners also states that within a few years that number will have risen to one million patients.

And, it estimates the total German cannabis market will be worth €16.2bn billion by 2028, with the medicinal cannabis market estimated to be worth €7.7bn by the same time.

This comes as Canadian firm Aphria, one of the few from that country to be currently showing a profit, say that by next year Germany will be contributing almost half it revenues. 

In a first quarter results announcement Aphria said with 2020 revenue projections estimated at $700m, its ‘German distribution business will represent slightly more than half of the total net revenue’. 

Daragh Anglim, Managing Director Prohibition Partners, says in the introduction to the report that the rapid growth of the German market ‘is unprecedented in Europe’. 

Adding: “Major change has followed across the continent but Germany remains one of the most open, promising and exciting markets in the region.” 

The report, which was released in October, last year, highlights the supply problems facing the German market which is currently reliant on imports from Canada, Holland, Portugal and Australia.

In an effort to combat this production licences were granted earlier this year, and of the 13 lots, Aphria and Aurora secured five, and Demecan received the remaining three lots. 

Each lot allows the holder to grow 200 kilograms per year for a four-year period. And the report adds: “The reality is that the German tendered facilities are not going to meet the domestic medical cannabis quantity demand.” 

It says patients requesting medical cannabis are being supported by a robust public health insurance regime, which covers 90% of the population.

The monthly allowance 100 grammes is generous and the ‘insurance companies cover all cannabis treatments and do not specify which conditions are covered’. 

Medical cannabis in Germany is very expensive, however, with an average price to patients of between €20 and €25 per gram for flower. 

In the Netherlands, medical cannabis is sold to patients for approximately €7 per gram, says the report.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.


Please enter your comment!
Please enter your name here

Latest news

European Moves To Brand CBD A ‘Narcotic’ Are A Growing Threat To Industry

MOVES are underway in Brussels to the restrict the sale of CBD across Europe with questions being...

UK CBD Pioneers To More Than Double Sales To Over £6m Following Canadian Takeover

CBD brand Love Hemp has been turbo-charged following its purchase by North American investors as it looks...

Legal UK Cannabis Industry Mapped Out For First Time – And Poised For Rapid Change

SOME say it's journalists who sketch history’s initial draft but this attempt to map-out the UK’s cannabis...

CBD Firms To Get Key Opportunity To Quiz FSA On Novel Food Compliance – For Free

THE European CBD industry is being given an opportunity to quiz UK regulators over the thorny issue...


UK Medicinal Cannabis Impasse – ‘Companies Won’t Invest In Clinical Trials; Medics Only Want Clinical Trials’

A WORLD-LEADING cannabis professor says the UK is caught in a depressing Catch-22 with companies unwilling to...

Europe’s Capital Markets Poised To Open-Up To The Cannabis Industry

THE European public markets are still a capital cocoon for cannabis with regulatory issues and the recent...

Must read


You might also likeRELATED
Recommended to you